Anti-Ustekinumab Antibody, pAb, Rabbit

Ustekinumab with trade name Stelara, is an FDA-approved drug to Crohn's disease, Ulcerative Colitis, Plaque Psoriasis and Psoriatic Arthritis, targeting both interleukins (IL)-12 and IL-23. Ustekinumab is a fully human immunoglobulin G1 kappa mAb that binds to IL-12 and IL-23. Ustekinumab binds to the p40 subunit common to IL-12 and IL-23 and prevents their interaction with the IL-12 receptor β1 subunit of the IL-12 and IL-23 receptor complexes, thereby disrupting the proinflammatory pathway. GenScript Anti-Ustekinumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Ustekinumab. Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.